Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Guidelines for management of urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.
Iyer, Renuka , Acquisto, Susan, Choti, Michael A., Hong, Theodore S. , Kis, Béla , Mead, Peter A., Roberts, Lewis R. , Parikh, Neehar D. , Siegel, Richard S., Whisenant, Jonathan, Cherepanov, Dasha , Broder, Michael S. , Roberts, Lewis R , Parikh, Neehar D , Bridgewater, John , Roberts, Rebecca, Sicklick, Jason Keith , Valle, Juan W.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e15641-e15641

10.1200/jco.2017.35.15_suppl.e15641 Get It

e15641 Background: CC pts with biliary stents or catheters are prone to have obstruction/infection and studies show 20-40% present with fever/or jaundice requiring urgent treatment for which there is no uniform guideline. We aimed to develop an expert panel consensus on this topic using the modified RAND/UCLA Delphi process to rate treatment appropriateness. Methods: We recruited 13 physician experts from relevant specialty, geography, and practice settings. Patient scenarios were developed and panelists rated the therapies before and after a face-to-face discussion. The appropriateness of various therapies was rated on a 1-9 scale and classified as appropriate, inappropriate, or uncertain. Scenarios with > 2 ratings of 1-3 (inappropriate) and > 2 ratings of 7-9 (appropriate) were considered to have disagreement and were not assigned an appropriateness rating. Results: Panelists were from all US regions (92%) and the UK (8%); had practiced for a mean 16.5 years (4-33 years). Panelists rated 480 scenarios before the meeting, but re-rated only 288 clinical scenarios as they felt that ongoing treatment with chemotherapy did not influence decision-making. Disagreement decreased from 37.5% before the meeting to 10.4% after. Consensus statements are summarized in the table below. Conclusions: The Delphi process produced consensus guidelines to fill an unmet need in urgent management of ascending cholangitis in pts with CC. (Support: The Cholangiocarcinoma Foundation). [Table: see text]
Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance).
Hua, Xinwei , Banbury, Barbara L. , Phipps, Amanda I. , Kocarnik, Jonathan, Harrison, Tabitha A. , Thibodeau, Stephen N. , Chan, Emily , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Jahagirdar, Balkrishna, Peters, Ulrike , Harrison, Tabitha A , Newcomb, Polly A. , Sun, Wei , Shi, Qian , Sinicrope, Frank A. , Gill, Sharlene , Alberts, Steven R. , Chan, Andrew T.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3604-3604

10.1200/jco.2017.35.15_suppl.3604 Get It

3604 Background: Limited research has investigated the role of variation in the host genome as a determinant of colon carcinoma (CC) outcomes, including toxicity due to therapeutic agents. We examined the relationship between germline genetic factors and treatment-associated serious adverse events (SAEs) in a population of CC patients in which treatment was standardized and follow-up for outcomes was uniformly conducted. Methods: Using existing biospecimens from CC patients with resected stage III disease in a phase III randomized trial of FOLFOX adjuvant chemotherapy with and without cetuximab (NCCTG N0147), genome-wide genotyping arrays were conducted for 2200 patients for a total of ~20 million single nucleotide polymorphisms (SNPs). Using logistic regression models we assessed SNP-specific associations with SAEs, utilizing a discovery-based approach to search the genome in an unbiased manner. Detailed information on SAEs was collected using the Common Toxicity Criteria for Adverse Events (CTCAE, v3.0). Analyses evaluating associations with specific classes of common grade ≥3 SAEs were performed, including gastrointestinal toxicities, neutropenia, and paresthesias. A threshold of P < 5x10-8was used to denote genome-wide significance. Results: Among patients who received FOLFOX, several SNPs on chr 15 near the ANP32A gene and on chr 2 near the CD207 gene were statistically significantly associated with grade ≥3 neuropathy. The strongest SNP-specific associations in these regions were in the range of odds ratio (OR) = 1.3, P = 2.8×10−10 and OR = 1.5, P = 2.7×10−10, respectively. Conclusions: Findings from this genome-wide analysis demonstrate the potential importance of germline genetic variation in influencing CC patients’ experience of specific toxicities to FOLFOX regimens. These results highlight two genomic regions of potential interest for understanding the biological mechanism for such toxicities, although further evaluation and replication is needed. Support: U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, CCSRI 021039, R01CA176272, Eli Lilly & Co, Pfizer, Sanofi. Clinical trial information: NCT00079274 .
SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy.
Budd, G. Thomas , Hobday, Timothy J. , Stewart, James A. , Salim, Muhammad , Cho, Jonathan K., Rinn, Kristine , Albain, Kathy S. , Chew, Helen K. , Burton, Gary V., Moore, Timothy D., Srkalović, Gordan , Flaherty, Lawrence E. , Livingston, Robert B., Lew, Danika L., Barlow, William E. , Moore, Halle C. F. , Isaacs, Claudine , McGregor, Bradley A. , Gralow, Julie R. , Hortobágyi, Gabriel N.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 521-521

10.1200/jco.2017.35.15_suppl.521 Get It

521 Background: S0221 investigated weekly vs q 2 week dosing of doxorubicin/cyclophosphamide (AC) and paclitaxel (P) in patients (pts) with high risk early breast cancer as previously reported (JCO 33:58-64, 2015). After enrollment of 2716 pts randomization to the two AC arms was stopped for futility and an additional 578 pts received 4 cycles of q 2 week AC and were randomized to P weekly (Pw) or P q 2 weeks (P2). We report updated results of the original trial design and the first report of the 578 pts treated with AC x 4 and Pw x 12 or P2 x 6. Methods: Between December 2003 and November 2010, 2716 pts were randomized in a 2x2 factorial design to 1) 15 weeks of weekly AC (A 24 mg/m2/week and C 60 mg/m2/day po) vs 6 cycles of q 2 week AC (A 60 mg/m2 and C 600 mg/m2) and 2) Pw (paclitaxel 80 mg/m2/week x 12) vs P2 (paclitaxel 175 mg/m2 q 2 weeks x 6), with growth factor support as previously described. After study amendment 578 patients received 4 cycles of q 2 week AC followed by Pw or P2. Updated survival was assessed using log-rank tests and Cox regression models. Results: At a median follow-up of 8.5 years, among the pts treated in the original protocol, there were no significant differences among the four treatments for DFS (p=0.21) or OS (p=0.08). The triple-negative subset had worse DFS (P<0.001) than the HER2-positive or ER/PR+/HER2- subsets, with 5 year DFS of 75% vs 83% and 84%, respectively. While we previously found in the triple negative subset that the arm using q 2 weeks for both AC and paclitaxel was marginally superior, the differences among the arms are no longer significant for DFS (p=0.12) or OS (p=0.11). Among the 578 pts assigned ACx4 and randomized to Pw v P2 there were no overall differences in DFS (p=0.70) or OS (p=0.63) after 4.4 years median follow-up. Conclusions: There were no significant differences in DFS or OS between any of the schedules with extended follow-up in the original cohort and no difference in outcome by paclitaxel schedule for the 578 additional patients in the revised protocol. Either paclitaxel schedule may be recommended, with selection based on toxicity, cost, or patient preference rather than efficacy. Support: NCI grants CA32102, CA38926, CA21115, CA21076, CA77597, CA25224, CA77202, CCSRI15469, and Amgen, Inc. Clinical trial information: NCT00070564.
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
Camidge, D. Ross , Demedts, Ingel , Grosch, Heidrun, Mercurio, Jean-Pierre Di , Molina, Julian R. , Bepler, Gerold , Lewanski, C., Wijayawardana, Sameera R. , Wang, Xuejing Aimee , Morán, Teresa , Mileham, Kathryn Finch , Juan, Óscar , Goldman, Jonathan W. , Park, Keunchil , Wallin, Johan Erik , Wacheck, Volker , Smit, Egbert F

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9070-9070

10.1200/jco.2016.34.15_suppl.9070 Get It

Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
Galsky, Matt D., Dawson, Nancy A. , Srinivas, Sandy, Vaishampayan, Ulka N. , Drakaki, Alexandra , Powles, Thomas, Hoffman‐Censits, Jean , Cui, Na , Mariathasan, Sanjeev , Thastrom, Ann Christine, Abidoye, Oyewale O., Bajorin, Dean F. , Vaishampayan, Ulka , Balar, Arjun Vasant , Loriot, Yohann , Necchi, Andrea , Joseph, Richard W. , Sridhar, Srikala S , Quinn, David I , Drakaki, Alexandra , Durán, Ignacio , Rosenberg, Jonathan E , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: LBA4500-LBA4500

10.1200/jco.2016.34.15_suppl.lba4500 Get It

A phase 1b/2 study combining MM-151 + nal-IRI + 5-FU + leucovorin in RAS-wildtype metastatic colorectal cancer (mCRC).
Chan, Emily , Harb, Wael A., Mody, Kabir , Jiang, Xiaoy, McClure, Ty, Valencia, A. Gonzalez, Fitzgerald, Jonathan B., Pipas, J. Marc , Nering, Rachel, Kearns, Jeffrey D. , Lewis, Lionel D.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS3633-TPS3633

10.1200/jco.2016.34.15_suppl.tps3633 Get It

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
Petrylak, Daniel P. , Heijden, Michiel Simon Van Der, O’Donnell, Peter H. , Retz, Margitta, Grivas, Petros , Boyd, Zachary, Nickles, Dorothee , Hegde, Priti S., Mariathasan, Sanjeev , Rosenberg, Jonathan E , Necchi, Andrea , Loriot, Yohann , Perez‐Gracia, José Luis , Bellmunt, Joaquim , Joseph, Richard W. , Fong, Lawrence , Kadel, Edward E. , Frampton, Garrett M. , Bourgon, Richard , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 104-104

10.1200/jco.2016.34.15_suppl.104 Get It

A Capacity Allocation Planning Model for Integrated Care and Access Management
Deglise‐Hawkinson, Jivan, Huschka, Todd R., Kaufman, David L. , Oyen, Mark P. Van , Huschka, Todd, Helm, Jonathan Eugene

Mayo Clinic

Production and Operations Management | September 6, 2018 | Volume: 27 | Issue: 12 | Pages: 2270-2290

10.1111/poms.12941 | PMID 30930608 Get It

The prevailing first‐come‐first‐served approach to outpatient appointment scheduling ignores differing urgency levels, leading to unnecessarily long waits for urgent patients. In data from a partner healthcare organization, we found in some departments that urgent patients were inadvertently waiting longer for an appointment than non‐urgent patients. This study develops a capacity allocation optimization methodology that reserves appointment slots based on urgency in a complicated, integrated care environment where multiple specialties serve multiple types of patients. This optimization reallocates network capacity to limit access delays (indirect waiting times) for initial and downstream appointments differentiated by urgency. We formulate this problem as a queueing network optimization and approximate it via deterministic linear optimization to simultaneously smooth workloads and guarantee access delay targets. In a case study of our industry partner we demonstrate the ability to (i) reduce urgent patient mean access delay by 27% with only a 7% increase in mean access delay for non‐urgent patients, and (ii) increase throughput by 31% with the same service levels and overtime.
Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.
Martin, Peter , Thompson, Carrie A. , Lossos, Izidore S. , Allmer, Cristine, Feldman, Andew L., Friedberg, Jonathan W. , Flowers, Christopher R. , Famà, Angelo , Casulo, Carla , Nastoupil, Loretta J. , Link, Brian K. , Kahl, Brad S. , Maurer, Matthew J. , Jaye, David L. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 10042-10042

10.1200/jco.2018.36.15_suppl.10042 Get It

Outcomes with chemotherapy for metastatic non-small cell lung cancer (mNSCLC) in patients previously treated with immune checkpoint inhibitors (CPI).
Elnair, Radowan , Chang, Guy vin, Powell, Steven , Sumey, Christopher , Bleeker, Jonathan

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e21119-e21119

10.1200/jco.2018.36.15_suppl.e21119 Get It